FR2951172B1 - Derives pyrazolopyridines en tant qu'agent anticancereux - Google Patents

Derives pyrazolopyridines en tant qu'agent anticancereux

Info

Publication number
FR2951172B1
FR2951172B1 FR0957140A FR0957140A FR2951172B1 FR 2951172 B1 FR2951172 B1 FR 2951172B1 FR 0957140 A FR0957140 A FR 0957140A FR 0957140 A FR0957140 A FR 0957140A FR 2951172 B1 FR2951172 B1 FR 2951172B1
Authority
FR
France
Prior art keywords
cancer agent
pyrazolopyridine derivatives
pyrazolopyridine
derivatives
cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
FR0957140A
Other languages
English (en)
Other versions
FR2951172A1 (fr
Inventor
Karim Bedjeguelal
Remi Rabot
El Bachir Kaloun
Patrice Mayer
Arnaud Marchand
Nicolas Rahier
Philippe Schambel
Hugues Bienayme
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pierre Fabre Medicament SA
Original Assignee
Pierre Fabre Medicament SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pierre Fabre Medicament SA filed Critical Pierre Fabre Medicament SA
Priority to FR0957140A priority Critical patent/FR2951172B1/fr
Priority to EP10770774.7A priority patent/EP2488519B1/fr
Priority to JP2012533621A priority patent/JP5833010B2/ja
Priority to PCT/EP2010/065346 priority patent/WO2011045344A1/fr
Priority to US13/500,757 priority patent/US8889711B2/en
Publication of FR2951172A1 publication Critical patent/FR2951172A1/fr
Application granted granted Critical
Publication of FR2951172B1 publication Critical patent/FR2951172B1/fr
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
FR0957140A 2009-10-13 2009-10-13 Derives pyrazolopyridines en tant qu'agent anticancereux Expired - Fee Related FR2951172B1 (fr)

Priority Applications (5)

Application Number Priority Date Filing Date Title
FR0957140A FR2951172B1 (fr) 2009-10-13 2009-10-13 Derives pyrazolopyridines en tant qu'agent anticancereux
EP10770774.7A EP2488519B1 (fr) 2009-10-13 2010-10-13 Dérivés de pyrazolopyridine comme agent anticancer
JP2012533621A JP5833010B2 (ja) 2009-10-13 2010-10-13 抗癌剤としてのピラゾロピリジン誘導体
PCT/EP2010/065346 WO2011045344A1 (fr) 2009-10-13 2010-10-13 Dérivés de pyrazolopyridine comme agent anticancer
US13/500,757 US8889711B2 (en) 2009-10-13 2010-10-13 Pyrazolopyridine derivatives as anticancer agent

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR0957140A FR2951172B1 (fr) 2009-10-13 2009-10-13 Derives pyrazolopyridines en tant qu'agent anticancereux

Publications (2)

Publication Number Publication Date
FR2951172A1 FR2951172A1 (fr) 2011-04-15
FR2951172B1 true FR2951172B1 (fr) 2014-09-26

Family

ID=42112290

Family Applications (1)

Application Number Title Priority Date Filing Date
FR0957140A Expired - Fee Related FR2951172B1 (fr) 2009-10-13 2009-10-13 Derives pyrazolopyridines en tant qu'agent anticancereux

Country Status (5)

Country Link
US (1) US8889711B2 (fr)
EP (1) EP2488519B1 (fr)
JP (1) JP5833010B2 (fr)
FR (1) FR2951172B1 (fr)
WO (1) WO2011045344A1 (fr)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8754114B2 (en) 2010-12-22 2014-06-17 Incyte Corporation Substituted imidazopyridazines and benzimidazoles as inhibitors of FGFR3
DE102011105469A1 (de) * 2011-06-24 2012-12-27 Merck Patent Gmbh 7-Azaindolderivate
WO2013045413A1 (fr) * 2011-09-27 2013-04-04 Sanofi Dérivés d'amide d'acide 6-(4-hydroxyphényl)-3-alkyl-1h-pyrazolo[3,4-b] pyridine-4-carboxylique utilisés comme inhibiteurs de kinase
US10138235B2 (en) 2011-12-14 2018-11-27 Sanofi Pyrazolopyridine derivatives, preparation process therefor and therapeutic use thereof
FR2984325A1 (fr) * 2011-12-14 2013-06-21 Sanofi Sa Derives de pyrazolopyridine, leur procede de preparation et leur application en therapeutique
FR2985257B1 (fr) * 2011-12-28 2014-02-14 Sanofi Sa Composes dimeres agonistes des recepteurs des fgfs (fgfrs), leur procede de preparation et leur application en therapeutique
CN103214470A (zh) * 2012-01-18 2013-07-24 杨更亮 酮类与吲哚衍生物反应合成的新型抗癌化合物
WO2013167403A1 (fr) * 2012-05-09 2013-11-14 Sanofi Dérivés de 6-(4-hydroxyphényl)-1h-pyrazolo[3,4-b]pyridine substitués utilisés comme inhibiteurs de kinases
UA117347C2 (uk) 2012-06-13 2018-07-25 Інсайт Холдинґс Корпорейшн Заміщені трициклічні сполуки як інгібітори fgfr
JPWO2013187462A1 (ja) 2012-06-14 2016-02-08 第一三共株式会社 ピペリジニルピラゾロピリジン誘導体
EP2867236B1 (fr) 2012-06-29 2017-06-14 Pfizer Inc Nouvelles 7h-pyrrolo[2,3-d]pyrimidines substituées par un groupe amino en position 4, utilisées comme inhibiteurs de lrrk2
WO2014026125A1 (fr) 2012-08-10 2014-02-13 Incyte Corporation Dérivés de pyrazine en tant qu'inhibiteurs de fgfr
US9266892B2 (en) * 2012-12-19 2016-02-23 Incyte Holdings Corporation Fused pyrazoles as FGFR inhibitors
US9045477B2 (en) * 2013-03-15 2015-06-02 Epizyme, Inc. Substituted 6,5-fused bicyclic heteroaryl compounds
US9776996B2 (en) 2013-03-15 2017-10-03 Epizyme, Inc. Substituted 6,5-fused bicyclic heteroaryl compounds
CN105263931B (zh) 2013-04-19 2019-01-25 因赛特公司 作为fgfr抑制剂的双环杂环
JP6487921B2 (ja) 2013-12-17 2019-03-20 ファイザー・インク ＬＲＲＫ２阻害薬としての新規の３，４−二置換−１Ｈ−ピロロ［２，３−ｂ］ピリジンおよび４，５−二置換−７Ｈ−ピロロ［２，３−ｃ］ピリダジン
WO2016012896A1 (fr) 2014-07-24 2016-01-28 Pfizer Inc. Composés de pyrazolopyrimidine
US10851105B2 (en) 2014-10-22 2020-12-01 Incyte Corporation Bicyclic heterocycles as FGFR4 inhibitors
WO2016115272A1 (fr) 2015-01-13 2016-07-21 Vanderbilt University Composés à substituants benzothiazole et benzisothiazole en tant que potentialisateurs allostériques de mglur4, compositions, et méthodes de traitement de dysfonctionnements neurologiques
UA121669C2 (uk) 2015-02-20 2020-07-10 Інсайт Корпорейшн Біциклічні гетероцикли як інгібітори fgfr
WO2016134294A1 (fr) 2015-02-20 2016-08-25 Incyte Corporation Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4
MA41551A (fr) 2015-02-20 2017-12-26 Incyte Corp Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4
US20180170942A1 (en) * 2015-06-16 2018-06-21 Nantbio, Inc. Polycyclic derivatives targeting ral gtpases and their therapeutical applications
MX2018000577A (es) * 2015-07-16 2018-09-05 Array Biopharma Inc Compuestos de pirazolo[1,5-a]piridina sustituidos como inhibidores de la ret quinasa.
RU2722149C1 (ru) 2015-09-14 2020-05-27 Пфайзер Инк. Новые производные имидазо[4,5-c] хинолинов и имидазо[4,5-c][1,5] нафтиридинов в качестве ингибиторов LRRK2
AU2017294231B2 (en) * 2016-07-05 2021-09-09 Guangzhou Maxinovel Pharmaceuticals Co., Ltd Aromatic acetylene or aromatic ethylene compound, intermediate, preparation method, pharmaceutical composition and use thereof
JOP20190077A1 (ar) 2016-10-10 2019-04-09 Array Biopharma Inc مركبات بيرازولو [1، 5-a]بيريدين بها استبدال كمثبطات كيناز ret
TWI704148B (zh) 2016-10-10 2020-09-11 美商亞雷生物製藥股份有限公司 作為ｒｅｔ激酶抑制劑之經取代吡唑并[1,5-a]吡啶化合物
JP6888101B2 (ja) 2017-01-18 2021-06-16 アレイ バイオファーマ インコーポレイテッド ＲＥＴキナーゼ阻害剤としての置換ピラゾロ［１，５−ａ］ピラジン化合物
AR111473A1 (es) * 2017-04-19 2019-07-17 Sumitomo Chemical Co Método para la preparación de compuesto de piridina
AR111960A1 (es) 2017-05-26 2019-09-04 Incyte Corp Formas cristalinas de un inhibidor de fgfr y procesos para su preparación
CA3069990A1 (fr) 2017-08-01 2019-02-07 Theravance Biopharma R&D Ip, Llc Composes bicycliques pyrazolo et triazolo utilises en tant qu'inhibiteurs de kinase jak
CN109988144A (zh) 2017-12-29 2019-07-09 广州再极医药科技有限公司 芳香乙烯或芳香乙基类衍生物、其制备方法、中间体、药物组合物及应用
JP7060694B2 (ja) 2018-01-18 2022-04-26 アレイ バイオファーマ インコーポレイテッド Ｒｅｔキナーゼ阻害剤としての置換ピロロ［２，３－ｄ］ピリミジン化合物
CN111615514B (zh) 2018-01-18 2022-10-11 奥瑞生物药品公司 作为ret激酶抑制剂的取代的吡唑并[4,3-c]吡啶化合物
CN111630054B (zh) 2018-01-18 2023-05-09 奥瑞生物药品公司 作为RET激酶抑制剂的取代的吡唑并[3,4-d]嘧啶化合物
SG11202010636VA (en) 2018-05-04 2020-11-27 Incyte Corp Solid forms of an fgfr inhibitor and processes for preparing the same
MA52493A (fr) 2018-05-04 2021-03-10 Incyte Corp Sels d'un inhibiteur de fgfr
JP2022500383A (ja) 2018-09-10 2022-01-04 アレイ バイオファーマ インコーポレイテッド Ｒｅｔキナーゼ阻害剤としての縮合複素環式化合物
CN113498352A (zh) 2019-01-23 2021-10-12 施万生物制药研发Ip有限责任公司 作为jak抑制剂的咪唑并[1,5-a]吡啶、1,2,4-***并[4,3-a]吡啶和咪唑并[1,5-a]吡嗪
US11628162B2 (en) 2019-03-08 2023-04-18 Incyte Corporation Methods of treating cancer with an FGFR inhibitor
WO2021007269A1 (fr) 2019-07-09 2021-01-14 Incyte Corporation Hétérocycles bicycliques en tant qu'inhibiteurs de fgfr
PE20221085A1 (es) 2019-10-14 2022-07-05 Incyte Corp Heterociclos biciclicos como inhibidores de fgfr
WO2021076728A1 (fr) 2019-10-16 2021-04-22 Incyte Corporation Hétérocycles bicycliques en tant qu'inhibiteurs de fgfr
WO2021113479A1 (fr) 2019-12-04 2021-06-10 Incyte Corporation Hétérocycles tricycliques en tant qu'inhibiteurs de fgfr
CN115151539A (zh) 2019-12-04 2022-10-04 因赛特公司 Fgfr抑制剂的衍生物
CA3220274A1 (fr) 2021-06-09 2022-12-15 Incyte Corporation Heterocycles tricycliques en tant qu'inhibiteurs de fgfr
WO2024067773A1 (fr) * 2022-09-29 2024-04-04 Insilico Medicine Ip Limited Inhibiteurs de tead et méthodes d'utilisation associées

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3687516T2 (de) * 1985-12-13 1993-07-29 American Cyanamid Co Neue kondensierte pyridinverbindungen, zwischenverbindungen fuer die herstellung und ihre verwendung als herbizide wirkstoffe.
US4822799A (en) * 1988-01-27 1989-04-18 Sandoz Pharm. Corp. Pyrazolopyridine analogs of mevalonolactone and derivatives thereof useful for inhibiting cholesterol biosynthesis in mammals
AU2003245700A1 (en) * 2002-02-12 2003-09-04 Glaxo Group Limited Pyrazolopyridine derivatives
KR20050069977A (ko) 2002-08-07 2005-07-05 미쯔비시 웰 파마 가부시키가이샤 디히드로피라졸로피리딘 화합물
US20040142978A1 (en) * 2002-12-12 2004-07-22 Pharmacia Corporation Aminocyanopyridine inhibitors of mitogen activated protein kinase-activated protein kinase-2
UA81453C2 (en) * 2003-02-27 2008-01-10 Pyrazolopyridine derivates
CA2532800C (fr) * 2003-07-23 2013-06-18 Exelixis, Inc. Modulateurs de la proteine alk (anaplastic lymphoma kinase) et leurs methodes d'utilisation
EP1763528B1 (fr) * 2004-07-05 2008-11-26 Astellas Pharma Inc. Derives de pyrazolopyridine
KR101011958B1 (ko) * 2005-08-25 2011-01-31 에프. 호프만-라 로슈 아게 ｐ38 ＭＡＰ 키나아제 저해제로서의 융합형 피라졸
WO2009006580A1 (fr) * 2007-07-05 2009-01-08 Cv Therapeutics, Inc. Dérivés de dihydropyridine, dihydropyrimidine et dihydropyrane facultativement condensés agissant comme bloqueurs des canaux calciques tardifs
US20100113415A1 (en) * 2008-05-29 2010-05-06 Rajapakse Hemaka A Epha4 rtk inhibitors for treatment of neurological and neurodegenerative disorders and cancer

Also Published As

Publication number Publication date
WO2011045344A1 (fr) 2011-04-21
US20120245170A1 (en) 2012-09-27
EP2488519A1 (fr) 2012-08-22
FR2951172A1 (fr) 2011-04-15
EP2488519B1 (fr) 2015-06-10
US8889711B2 (en) 2014-11-18
JP5833010B2 (ja) 2015-12-16
JP2013507425A (ja) 2013-03-04

Similar Documents

Publication Publication Date Title
FR2951172B1 (fr) Derives pyrazolopyridines en tant qu'agent anticancereux
FR23C1039I1 (fr) Derives de piperidinone carboxamide azaindane en tant qu'antagonistes du recepteur cgrp
HK1226394A1 (zh) 7-氮雜吲哚衍生物
BRPI1009118A2 (pt) 3h-imidazo[4,5-c] piridina-6-carboxamidas como agentes anti-inflamatórios
HK1210139A1 (en) Novel benzimidazole derivatives as ep4 antagonists ep4
SMT201500316B (it) Derivati di benzotiazolo come agenti anticancro
BRPI0919292A2 (pt) 3h-imidazo[4,5-b] piridina-6-carboxamidas como agentes anti-inflamatórios
FR3000492B1 (fr) Nouveaux derives azaindole en tant qu'inhibiteurs multikinases
BRPI1012697A2 (pt) derivados imidazo[1,2-a]piridina substituídos, composições farmacêuticas, e métodos de uso como inibidores da b-secretase
BRPI1008899A2 (pt) derivados 3,3´-espiroindolinona como agentes anticâncer
BRPI0914301A2 (pt) derivados de pirimidin-4-ona substituída
DK2401270T3 (da) Pyrazolderivater anvendt som CCR4-receptorantagonister.
IT1393337B1 (it) Sintesi di (4as, 7as)-ottaidro-1h-pirrolo[3,4-b]piridina
ZA201403195B (en) Pharmaceutical compositions of hydrophobic camptothecin derivatives
HRP20130641T1 (en) Pyridin-2-yl derivatives as immunomodulating agents
IT1393112B1 (it) Procedimento per la preparazione di derivati di prostaglandine
BRPI1008173A2 (pt) "derivados de piridina espiroindolinona"
BR112013013837A2 (pt) derivados de substituição de imidazoquinolina
IL218500A0 (en) Apogossypolone derivatives as anticaner agents
BR112012002678A2 (pt) Formulação de derivado de vitamina k3/nsa
BR112013013282A2 (pt) compostos de oxazolo[5,4-b]piridin-5-ila
DK2456765T3 (da) Imidazolderivater som mglur5-antagonister

Legal Events

Date Code Title Description
PLFP Fee payment

Year of fee payment: 7

PLFP Fee payment

Year of fee payment: 8

ST Notification of lapse

Effective date: 20180629